Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | IGF1R | P08069 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 3/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PYGL | P06737 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL81497 | 0.86 | IGF1R (0.63) | PNMTTAAR1IGF1RALOX15IDO1 | |
| SCHEMBL9026682 | 0.85 | IGF1R (0.67) | PNMTTAAR1IGF1RALOX15IDO1 | |
| SCHEMBL10609252 | 0.83 | IGF1R (0.65) | PNMTTAAR1IGF1RALOX15IDO1 | |
| SCHEMBL8905783 | 0.83 | IGF1R (0.65) | PNMTTAAR1IGF1RALOX15IDO1 | |
| SCHEMBL7008253 | 0.83 | IGF1R (0.65) | PNMTTAAR1IGF1RALOX15IDO1 | |
| SCHEMBL25218464 | 0.82 | ALDH1A1 (0.65) | PNMTTAAR1IGF1RALOX15ALDH1A1 | |
| SCHEMBL5454185 | 0.82 | KDM4E (0.65) | IGF1RALOX15ALDH1A1MAPTKDM4E | |
| SCHEMBL2299809 | 0.80 | ALDH1A1 (0.47) | PNMTTAAR1IGF1RALOX15IDO1 | |
| SCHEMBL12333663 | 0.80 | ALDH1A1 (0.47) | PNMTTAAR1IGF1RALOX15ALDH1A1 | |
| SCHEMBL3264645 | 0.80 | MAPT (0.47) | PNMTTAAR1IGF1RALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0767174-A1 | Novel aminoalkanephosphinic acids and their salts | CIBA-GEIGY AG (CH) | 1997-04-09 | — | — | EP | claimed |
| US-5376684-A | Aminobutyric acid antagonist; antiepileptic agent | CIBA-GEIGY CORPORATION (US) | 1994-12-27 | — | — | US | claimed |
| EP-0543780-A2 | Novel aminoalkanephosphinic acids and their salts | CIBA-GEIGY AG (CH) | 1993-05-26 | — | — | EP | claimed |
| US-12528773-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2026-01-20 | — | — | US | disclosed |
| CN-119546605-A | Protein degradation agent | 苏州开拓药业股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024027694-A9 | PROTEIN DEGRADATION AGENT | 苏州开拓药业股份有限公司 | 2025-01-02 | — | — | WO | disclosed |
| US-20240228502-A1 | 2-PHENYLAMINO PYRROLOPYRIMIDINES AS ACK1 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-11 | — | — | US | disclosed |
| WO-2024027795-A1 | ANTIBODY-DRUG CONJUGATE CONTAINING MYC PROTEIN DEGRADATION AGENT BIOACTIVE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 苏州开拓药业股份有限公司 | 2024-02-08 | — | — | WO | disclosed |
| WO-2024027694-A1 | PROTEIN DEGRADATION AGENT | 苏州开拓药业股份有限公司 | 2024-02-08 | — | — | WO | disclosed |
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-11-28 | — | — | US | disclosed |
| US-20230348387-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-11-02 | — | — | US | disclosed |
| WO-1991019707-A2 | ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES | THE UPJOHN COMPANY (US) | 1991-12-26 | — | — | WO | disclosed |
| EP-0459983-A1 | ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES | PHARMACIA & UPJOHN COMPANY (US) | 1991-12-11 | — | — | EP | disclosed |
| EP-0256888-B1 | BENZOTHIAZEPINE VASODILATORS HAVING ARALKYL SUBSTITUTION | McNeilab, Inc. (US) | 1991-07-03 | — | — | EP | disclosed |
| WO-1991009013-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1991-06-27 | — | — | WO | disclosed |
| EP-0411150-A1 | INDOLE DERIVATIVES, PREPARATION THEREOF, AND DRUG FOR PREVENTING AND TREATING NEPHRITIS CONTAINING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-06 | — | — | EP | disclosed |
| WO-1990006921-A1 | ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES | THE UPJOHN COMPANY (US) | 1990-06-28 | — | — | WO | disclosed |
| EP-0162208-B1 | NOVEL N-SUBSTITUTED 3,4-DIHYDROPYRIMIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS | SUNTORY KABUSHIKI KAISHA, also known as SUNTORY LTD. (JP) | 1989-11-23 | — | — | EP | disclosed |
| US-4729994-A | Benzothiazepine vasodilators having aralkyl substitution | MCNEILAB, INC. (US) | 1988-03-08 | — | — | US | disclosed |
| EP-0256888-A1 | Benzothiazepine vasodilators having aralkyl substitution | McNeilab, Inc. (US) | 1988-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348387-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | PNMT 3313/4885TAAR1 4166/4885IGF1R 2487/4885 |
| US-20240228502-A1 | 2-PHENYLAMINO PYRROLOPYRIMIDINES AS ACK1 INHIBITORS | ADCK1, DCK, TNKS2 | PNMT 4186/4885TAAR1 4717/4885IGF1R 2212/4885 |
| US-12528773-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, GAA | PNMT 4179/4885TAAR1 3606/4885IGF1R 1099/4885 |
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK7 | PNMT 721/4885TAAR1 1183/4885IGF1R 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.